高风险肺癌筛查的成本效益及项目效率的驱动因素
研究基于NLST参与者,用前列腺、肺、结直肠和卵巢癌筛查试验开发的风险预测工具进行回顾性风险分层,并以决策分析模型比较高风险筛查与标准诊疗。以6年风险2%为阈值可减少NLST需筛查人数81%;高风险筛查每获得1个质量调整生命年成本为20724加元(2015年加元),在每质量调整生命年10万加元支付意愿阈值下为成本效益(概率0.62),成本效益主要由非肺癌结局驱动。
要点
- 以6年风险2%为阈值,NLST中需筛查人数可减少81%。
- 高风险筛查每获1个质量调整生命年成本20724加元(2015年加元)。
- 在每质量调整生命年10万加元阈值下具成本效益的概率为0.62。
核心结论
- 非肺癌结局驱动了 diverse、烟草暴露人群中筛查的效率。
- 使用风险选择可降低预算影响;若非治愈性治疗成本继续上升,筛查甚至可能节省费用。
研究设计与样本
- 对NLST参与者用前列腺、肺、结直肠和卵巢癌筛查试验开发的风险预测工具进行回顾性识别。
- 比较高风险亚组与低风险亚组及加拿大PanCan观察性研究的肺癌发病率和人口学特征。
- 用决策分析模型比较高风险筛查与标准诊疗,数据来自NLST,费用采用PanCan研究的加拿大筛查与治疗成本。
- 进行了概率性和确定性敏感性分析以评估不确定性并识别项目效率驱动因素。
主要发现
- 使用前列腺、肺、结直肠和卵巢癌筛查试验开发的风险预测工具并以6年风险2%为阈值,会使NLST中需筛查人数减少81%。
- NLST中的高风险筛查参与者比PanCan研究中的对应人群具有更多不利的人口学特征。
- 高风险筛查每获得1个质量调整生命年成本为20724加元(2015年加元)。
- 在每质量调整生命年10万加元的支付意愿阈值下,高风险筛查被认为具成本效益,概率为0.62。
- 成本效益主要由非肺癌结局驱动;美国更高的非治愈性药物成本或当前免疫治疗和靶向治疗成本会使肺癌筛查成为节省费用的干预。
关键数值与推荐
- 风险预测工具阈值:6年风险2%。
- NLST中需筛查人数减少81%。
- 每获得1个质量调整生命年成本20724加元(2015年加元)。
- 支付意愿阈值每质量调整生命年10万加元下具成本效益的概率为0.62。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited. METHODS: Participants in the National Lung Cancer Screening Trial (NLST) were retrospectively identified with the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The high-risk subgroup was assessed for lung cancer incidence and demographic characteristics compared with those in the low-risk subgroup and the Pan-Canadian Early Detection of Lung Cancer Study (PanCan), which is an observational study that was high-risk-selected in Canada. A comparison of high-risk screening versus standard care was made with a decision-analytic model using data from the NLST with Canadian cost data from screening and treatment in the PanCan study. Probabilistic and deterministic sensitivity analyses were undertaken to assess uncertainty and identify drivers of program efficiency. RESULTS: Use of the risk prediction tool developed from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial with a threshold set at 2% over 6 years would have reduced the number of individuals who needed to be screened in the NLST by 81%. High-risk screening participants in the NLST had more adverse demographic characteristics than their counterparts in the PanCan study. High-risk screening would cost $20,724 (in 2015 Canadian dollars) per quality-adjusted life-year gained and would be considered cost-effective at a willingness-to-pay threshold of $100,000 in Canadian dollars per quality-adjusted life-year gained with a probability of 0.62. Cost-effectiveness was driven primarily by non-lung cancer outcomes. Higher noncurative drug costs or current costs for immunotherapy and targeted therapies in the United States would render lung cancer screening a cost-saving intervention. CONCLUSIONS: Non-lung cancer outcomes drive screening efficiency in diverse, tobacco-exposed populations. Use of risk selection can reduce the budget impact, and screening may even offer cost savings if noncurative treatment costs continue to rise.
引用
- Cressman S, Peacock SJ, Tammemägi MC, et al. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. J Thorac Oncol. 2017. PMID: 28499861. doi:10.1016/j.jtho.2017.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。